Views & Analysis Highs and lows in regenerative medicine How developments in gene editing and screening technology are advancing regenerative medicine.
News EU regulators back blood cancer stem cell therapy Molmed's treatment aims to prevent reduce risk of graft-versus-host disease.
News Teva walks away from Mesoblast's heart failure drug Mesoblast to continue developing stem cell based therapy.
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
